A Phase 1 interventional study of PF-06741086 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-12.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086 · Drug: Placebo
Biological: PF-06741086
PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
Placebo for PF-06741086, single dose
Also known as: saline placebo
Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs
Time frame: Day 1 up to Day 84
Percentage of subjects with laboratory abnormalities
Time frame: Day 1 up to Day 84
Number of subjects with change from baseline in vital signs
blood pressure, pulse rate, temperature, respiration rate
Time frame: Day 1 up to Day 84
Number of subjects with change from baseline in electrocardiogram (ECG) parameters
Time frame: Day 1 to Day 84
Percentage of subjects with changes from baseline in physical examination
Time frame: Day 1 to Day 84
Percentage of subjects with infusion site reactions
Time frame: Day 1 up to Day 7
Percentage of subjects with injection site reactions
Time frame: Day 1 to Day 7
Plasma PF-06741086 concentrations
Time frame: Day 1 up to Day 84
Maximum observed plasma concentration (Cmax)
Time frame: Day 1 up to Day 84
Time for Cmax (Tmax)
Time frame: Day 1 up to Day 84
Area under the curve from time zero to last quantifiable concentration (AUClast)
Time frame: Day 1 up to Day 84
Terminal half-life (t 1/2)
Time frame: Day 1 up to Day 84
Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)
Time frame: Day 1 up to Day 84
Volume of distribution at steady state (Vss)
Intravenous administration only
Time frame: Day 1 up to Day 84
Apparent volume of distribution (Vz/F)
Subcutaneous administration only
Time frame: Day 1 up to Day 84
Clearance (CL)
Intravenous administration only
Time frame: Day 1 up to Day 84
Apparent clearance (CL/F)
Subcutaneous administration only
Time frame: Day 1 up to Day 84
Bioavailability (F) [F = AUC (inf,sc) / AUC (inf,iv)]
Time frame: Day 1 up to Day 84
Mean residence time (MRT)
Time frame: Day 1 up to Day 84
Total tissue factor pathway inhibitor concentrations over time
Time frame: Day 1 up to Day 84
Thrombin generation
may include lag time, peak thrombin generation, and endogenous thrombin generation potential
Time frame: Day 1 up to Day 84
Prothrombin fragment 1+2 (PF1+2) concentrations over time
Time frame: Day 1 up to Day 84
D-dimer concentrations over time
Time frame: Day 1 up to Day 84
Dilute prothrombin time (dPT)
Time frame: Day 1 up to Day 84
Frequency of anti-drug antibody (ADA) and neutralizing antibody (NAb) production
Immunogenicity
Time frame: Day 1 up to Day 84
The record gives a start of Aug 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Marstacimab